In a case series, two patients with chordoma experienced responses to single-agent anti–programmed cell death ligand 1 (PD-L1) antibodies,149 and a review of patients enrolled in early-phase trials demonstrated that alveolar soft-part sarcoma was the most responsive subgroup to checkpoint blockade.91,150 The heterogeneity in the benefit of checkpoint inhibitors across sarcoma subtypes observed in these early-phase trials highlights the need for a precision approach to immunotherapy in these diverse tumors, and research to identify predictive biomarkers is warranted. This evidence concerns the gene CD274 and alveolar soft part sarcoma.